Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

Childhood obesity treatment reduces long-term health risks but not depression

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young adulthood.

21 Jan 2025

Benefits and risks of popular weight-loss drugs revealed

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity.

20 Jan 2025

Researchers create an atlas of health associations for GLP-1 receptor agonists

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for gastrointestinal and musculoskeletal issues.

20 Jan 2025

Intestinal bacterium found to reduce sugar intake in diabetic mice and humans

Excessive sugar consumption is linked to several non-communicable diseases, including obesity, cardiovascular disease, metabolic syndrome, and type 2 diabetes.

17 Jan 2025

AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing critical needs in cardiovascular health.

16 Jan 2025

Semaglutide improves glycemic control with automated insulin delivery

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin requirements and aiding weight management.

15 Jan 2025

Unveiling the hidden benefit of bariatric surgery

Welcoming a newborn is something many couples dream of doing, but it can get complicated when conceiving becomes a roadblock. Infertility affects one in six people, but obesity can also be a problem. When diet and exercise aren't enough to lose weight, bariatric surgery can become an option. Yet a new national survey by Orlando Health finds that 56% of Americans do not know that bariatric surgery is an effective way to improve fertility.

14 Jan 2025

Gut bacterium associated with reduced dietary sugar intake

This study links Ffar4, gut microbiota, and sugar preference, highlighting potential strategies for managing diabetes and obesity through dietary interventions.

13 Jan 2025

Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

9 Jan 2025

GLP-1 drugs linked to fewer post-surgical complications in diabetic patients

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery, according to a large study led by investigators at Weill Cornell Medicine, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.

6 Jan 2025

Do GLP-1 receptor agonists increase the risk of suicide in patients?

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal behaviors in high-risk populations.

6 Jan 2025

New Year, new approach to weight loss: Almost three quarters of UK women are considering using GLP-1s in 2025

As 2024 draws to a close, the new year ushers in the opportunity to set new goals for the year ahead. While weight-loss and fitness are staples of New Year resolutions they are commonly known to be the unsustainable resolutions that don't continue past January.

3 Jan 2025

Lithocholic acid enhances health and lifespan, mimicking calorie restriction

Lithocholic acid (LCA), a metabolite induced by calorie restriction (CR), activates AMPK and mimics anti-aging benefits. A recent study highlights LCA's role in improving muscle performance, glucose tolerance, and lifespan in aged organisms.

1 Jan 2025

Study finds racial and ethnic disparities in the use of obesity-management drugs

Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications to lower their weight compared with whites, new research suggests.

18 Dec 2024

Nutraceuticals: exploring potential benefits and challenges of an unregulated healthcare frontier

Nutraceuticals offer potential health benefits, from migraine relief to cognitive support, but safety and regulatory issues must be addressed for effective use.

18 Dec 2024

Danish studies find increased risk of optic nerve damage with diabetes medicine

Two independent studies from the University of Southern Denmark (SDU) show that patients with type 2 diabetes who are treated with the drug Ozempic have an increased risk of developing damage to the optic nerve of the eye, which can lead to severe and permanent loss of vision.

16 Dec 2024